For research use only. Not for therapeutic Use.
BMS-684 is a selective DGKα inhibitor with an IC50 of 15 nM. BMS-684 inhibits DGKα kinase activity with >100-fold selectivity over the related DGK type I family members DGKβ and DGKγ. BMS-684 does not inhibit any of the other seven DGK isozymes[1].
| Catalog Number | I040606 |
| CAS Number | 313552-29-3 |
| Synonyms | 4-(4-benzhydrylpiperazin-1-yl)-1-methyl-3-nitroquinolin-2-one |
| Molecular Formula | C27H26N4O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C27H26N4O3/c1-28-23-15-9-8-14-22(23)25(26(27(28)32)31(33)34)30-18-16-29(17-19-30)24(20-10-4-2-5-11-20)21-12-6-3-7-13-21/h2-15,24H,16-19H2,1H3 |
| InChIKey | XIVOLEKHEMYRBO-UHFFFAOYSA-N |
| SMILES | CN1C2=CC=CC=C2C(=C(C1=O)[N+](=O)[O-])N3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5 |
| Reference | [1]. Michael Wichroski, et al. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity. Sci Transl Med. 2023 Oct 25;15(719):eadh1892. |
